Associated Papers
Clinicopathological features of PDGFRA D842Y-mutant gastrointestinal stromal tumors: insights from four cases.
Kanda T et al.
International Cancer Conference Journal, 2026
Sporadic Multiple Gastrointestinal Stromal Tumors With Distinct KIT and PDGFRA Mutations in Two Separate Tumors: A Case Report and Literature Review.
Akincioglu E et al.
International Journal of Surgical Pathology, 2025
Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors (GISTs): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations.
Rodriquenz MG et al.
Cancer Medicine, 2025
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
DICER1 Mutational Spectrum in Intracranial CNS-Neoplasias-A Review and a Report from the CNS-InterREST GPOH Study Center.
Manea S et al.
Cancers, 2025
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.
Friker LL et al.
Acta Neuropathologica, 2025
Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib.
Muñoz-Mármol AM et al.
Cancers, 2025
Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research.
Cao L et al.
Global Medical Genetics, 2024
Genomic and transcriptomic landscape of human gastrointestinal stromal tumors.
Xie F et al.
Nature Communications, 2024
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
He C et al.
Current Treatment Options in Oncology, 2024
Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.
Andrade AF et al.
Nature Communications, 2024
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Hadad S et al.
Acta Neuropathologica, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Automated Dashboards for the Identification of Pathogenic Circulating Tumor DNA Mutations in Longitudinal Blood Draws of Cancer Patients.
Udalov A et al.
Methods and Protocols, 2023
Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars.
Skinner KR et al.
Biorxiv : the Preprint Server for Biology, 2023
Genomics-Driven Precision Medicine in Pediatric Solid Tumors.
Suthapot P et al.
Cancers, 2023
Cytogenetic and Molecular Characterization of IDH-Wildtype Glioblastomas and Grade 4 IDH-Mutant Astrocytomas with Unusual Histology.
Ahrendsen JT et al.
Journal of Neuropathology and Experimental Neurology, 2022
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS et al.
Cancer Genetics, 2022
Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
Higa N et al.
Neurologia Medico-chirurgica, 2022
CancerVar: An artificial intelligence-empowered platform for clinical interpretation of somatic mutations in cancer.
Li Q et al.
Science Advances, 2022
An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors.
Sun Y et al.
Frontiers in Oncology, 2022
Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.
Henriques-Abreu M et al.
Expert Review of Anticancer Therapy, 2021
Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma.
DeSisto J et al.
Nature Communications, 2021
Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice.
Steeghs EMP et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma.
He C et al.
Nature Communications, 2021
Mutational characteristics of gastrointestinal stromal tumors: A single-center analysis of 302 patients.
Liang L et al.
Oncology Letters, 2021
Update on Molecular Genetics of Gastrointestinal Stromal Tumors.
Brčić I et al.
Diagnostics (basel, Switzerland), 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Smrke A et al.
Future Oncology (london, England), 2020
Clinicopathologic characteristics, diagnostic clues, and prognoses of patients with multiple sporadic gastrointestinal stromal tumors: a case series and review of the literature.
Shen YY et al.
Diagnostic Pathology, 2020
Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients.
Li H et al.
Frontiers in Oncology, 2020
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1.
Lee JC et al.
Acta Neuropathologica, 2019
Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution.
Kaneva K et al.
Jco Precision Oncology, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
Indio V et al.
International Journal of Molecular Sciences, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
Farag S et al.
European Journal of Cancer (oxford, England : 1990), 2017
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.
Schaefer IM et al.
Nature Communications, 2017
Data on quantification of signaling pathways activated by KIT and PDGFRA mutants.
Bahlawane C et al.
Data in Brief, 2016
Structural and biochemical studies of the PDGFRA kinase domain.
Liang L et al.
Biochemical and Biophysical Research Communications, 2016
Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J et al.
Oncotarget, 2016
Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW et al.
Plos One, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics.
Bahlawane C et al.
Cell Communication and Signaling : Ccs, 2015
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H et al.
Human Pathology, 2014